Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1849 • ACR Convergence 2024
Selective Targeting of One-Carbon Metabolism to Combat Rheumatoid Arthritis
Theodora Manolakou¹, Sanjaykumar Boddul¹, George Sentis², Michail Angelos Panagias¹, Martina Samiotaki³, Dionysis Nikolopoulos¹, Ana Slipicevic¹, Kumar Sanjiv¹, Martin Henriksson¹, Oliver Mortusewicz¹, Aikaterini Chatzidionysiou¹, Per-Johan Jakobsson¹ and Thomas Helleday¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Biomedical Reseearch Foundation Academy of Athens, Athens, Greece, ³Alexander Fleming Biomedical Sciences Research Center, Athens, Greece
Background/Purpose: Rapidly proliferating cells fuel their increased nucleotide demand by boosting one-carbon metabolism, associated with the survival of pathogenic proliferative cells and the release of…
Abstract Number: 1915 • ACR Convergence 2024
Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting
Martha Delgado¹, Cassidy Hernandez-Tamayo², Melissa Wilson² and Leanna Wise³, ¹Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³LAGMC/Keck Medicine of USC, Los Angeles, CA
Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
Abstract Number: 2130 • ACR Convergence 2024
Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Improved disease control for articular manifestations of Rheumatoid arthritis (RA), has resulted in more attention being directed to extra-articular (ExRA) manifestations (cardiovascular events, osteoporosis,…
Abstract Number: 2219 • ACR Convergence 2024
Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
Tobias Manigold¹, Nicolas Bodmer², Rosoux Elisabeth³, Deborah Markham⁴, Guillaume Fahrni³, Raphael Micheroli⁵, Lucas Bachmann², Jonas Brändli⁶, Fabio Becce⁷ and Thomas Hügle⁸, ¹Department of Rheumatology, Inselspital University Hospital Bern, Bern, Switzerland., Bern, Switzerland, ²Medignition, Zürich, Switzerland, ³3) Department of Radiology, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland, Lausanne, Switzerland, ⁴Department of Rheumatology, University Hospital Lausanne (CHUV), Switzerland, Lausanne, Switzerland, ⁵University Hospital Zurich, Zurich, Switzerland, ⁶6) Data Science Team, Swiss Clinical Quality Management Foundation, Zurich, Switzerland, Zürich, Switzerland, ⁷Lausanne University Hospital (CHUV), Lausanne, Switzerland, ⁸Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) disease can mimic or interfere with the course of rheumatoid arthritis (RA). Previous studies suggest higher prevalence of Chondrocalcinosis…
Abstract Number: 2236 • ACR Convergence 2024
Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis
Maria Rydholm¹, Mohaned Hameed², Anna Eberhard², Ankita Sharma², Giovanni Cagnotto² and Carl Turesson², ¹Skåne University Hospital, Malmö, Sweden, ²Lund University, Malmö, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is characterized by polyarticular involvement of the hands, leading to impaired function. The impact of active inflammation on disability in early…
Abstract Number: 2255 • ACR Convergence 2024
Differences in Pharmacological Prescription to Patients with Recent-onset Arthritis: Analysis from the Gender Perspective
Maryia Nikitsina, María Ahijón Lana and Isidoro González-Álvaro, University Hospital La Princesa, Madrid, Madrid, Spain
Background/Purpose: Nowadays the honing in on sex-specific treatment options is the most productive way to move forward with the larger effort of implementing precision medicine.…
Abstract Number: 2274 • ACR Convergence 2024
Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Asger Reinstrup Bihlet¹, Philip G Conaghan², Thomas Boesen³, Mette Arnum Jensen³, Alejandro Castillo Mondragón⁴, Ema Erkocevic Petersen⁴, Cathrine Borgsted Bak⁴ and Thomas EN Jonassen³, ¹NBCD A/S, Soeborg, Denmark, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Synact Pharma ApS, Holte, Denmark, ⁴NBCD A/S, Soborg, Denmark
Background/Purpose: AP1189 is a novel, first-in-class, oral, biased melanocortin (MC)1 and MC3 receptor agonist in development for Rheumatoid Arthritis (RA) treatment. Through multiple actions including…
Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 0038 • ACR Convergence 2024
The Role of Dual Specificity Phosphatase 22 (DUSP22) in Rheumatoid Arthritis: Mechanism and Genetic Investigations
Wei-Ting Hung¹, Yi-Ming Chen², Wen-Nan Huang³, Tsai-Hung Yen⁴, Tse-Hua Tan⁵ and Huai-Chia Chuang⁶, ¹Taichung Veteran General Hospital, Taichung City, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China), ³Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ⁴Taichung Veterans General Hospital, Xitun District, Taichung City, Taiwan (Republic of China), ⁵National Health Research Institutes, Mao-Li, Taiwan (Republic of China), ⁶National Health Research Institutes, Zhunan, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. This study investigates the role of Dual Specificity Phosphatase…
Abstract Number: 0055 • ACR Convergence 2024
Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Katharine moosic¹, Thomas Olson², Mark Freijat³, samara khalique⁴, Cait Hamele¹, Bryna Shemo¹, Jesse Boodoo⁵, William Baker⁶, Gitanjali Khurana⁷, Matthew Schmachtenberg⁸, Tristin Duffy⁸, Aakrosh Ratan¹, Erika Darrah⁹, Felipe Andrade¹⁰, Marieke Jones⁸, Kristine Olson², David Feith¹, Thomas Loughran¹ and Donald Kimpel¹, ¹University of Virginia, Charlottesville, VA, ²Virginia Commonwealth University, Richmond, VA, ³Flow Rheumatology, Scottsdale, AZ, ⁴Carilion Clinic/ VirginiaTech, Salem, VA, ⁵Sarasota Arthritis Center, Sarasota, FL, ⁶Atrium Health, Charlotte, NC, ⁷University of Virginia, CROZET, VA, ⁸University of Virginia, Charlottesville, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
Abstract Number: 0135 • ACR Convergence 2024
Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
James Galloway¹, Victoria Basey², Saqib Rana³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is higher in patients with rheumatoid arthritis (RA) compared to the general population; however whether this risk changes with…
Abstract Number: 0216 • ACR Convergence 2024
Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?
Betul Ibis and Furkan Bahar, Mount Auburn Hospital/Harvard Medical School, Watertown, MA
Background/Purpose: During the past decade, antibody-based immunotherapies (including anti-PD1, anti-PD-L1, and anti-CTLA4) have revolutionized cancer treatment by enhancing the body's immune response against tumors. However,…
Abstract Number: 0360 • ACR Convergence 2024
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³ and René-Marc Flipo⁴, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Hôpital Roger Salengro, France, Lille, France
Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…
Abstract Number: 0459 • ACR Convergence 2024
Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo
Dovile Sinkeviciute¹, Sofie Falkenloeve Madsen², Nicolas Willumsen³, Patryk Drobinski³, Morten Karsdal³ and Anne-Christine Bay-Jensen³, ¹Nordic Bioscience, Herlev, Hovedstaden, Denmark, ²University of Copenhagen, Copenhagen N, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].